Constitutive STAT3 activation is often displayed by various carcinomas including prostate cancer, and pharmacological drugs that can abrogate deregulated STAT3 activation may have a potential for cancer therapy [32, 33]. This evidence concerns the gene STAT3 and carcinoma.